

10595108

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HCAPLUS' AT 18:09:06 ON 12 APR 2007
FILE 'HCAPLUS' ENTERED AT 18:09:06 ON 12 APR 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.20	218.76

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.80	260.36

FILE 'REGISTRY' ENTERED AT 18:18:23 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1
DICTIONARY FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\34343ol.str

L5 STRUCTURE uploaded

=> s 15
SAMPLE SEARCH INITIATED 18:19:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

Updated Search

10595108

100.0% PROCESSED 7 ITERATIONS
SEARCH TIME: 00.00.01

7 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 7 TO 298

L6 7 SEA SSS SAM L5

=> s 15 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 18:19:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 121 TO ITERATE

100.0% PROCESSED 121 ITERATIONS
SEARCH TIME: 00.00.01

120 ANSWERS

L7 120 SEA SSS FUL L5

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
172.55 432.91

FILE 'HCAPLUS' ENTERED AT 18:19:26 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 16
FILE LAST UPDATED: 11 Apr 2007 (20070411/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17
L8 3 L7

=> s 18 and bailey, m?/au
1157 BAILEY, M?/AU
L9 2 L8 AND BAILEY, M?/AU

=> d 19, ibib abs hitstr, 1-2

Updated Search

10595108

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:15038 HCAPLUS
DOCUMENT NUMBER: 144:108608
TITLE: Preparation of peptide analogs as hepatitis C
inhibitors
INVENTOR(S): Bailey, Murray D.; Bhardwaj, Punit;
Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie;
Halmos, Teddy; Llinas-Brunet, Montse; Poupart,
Marc-Andre; Rancourt, Jean
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany;
Boehringer Ingelheim Pharma GmbH & Co KG; Bailey,
Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro,
Elise; Goudreau, Nathalie; Halmos, Teddy;
Llinas-Brunet, Montse; et al.
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006000085	A1	20060105	WO 2005-CA967	20050622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2556669	A1	20060105	CA 2005-2556669	20050622
EP 1763531	A1	20070321	EP 2005-759498	20050622
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006258868	A1	20061116	US 2006-595108	20060217
PRIORITY APPLN. INFO.:			US 2004-583543P	P 20040628
OTHER SOURCE(S): GI	MARPAT 144:108608		WO 2005-CA967	W 20050622

Want app

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to peptides I [n, m are 1 or 2; R1 is H, (halo)alkyl, (halo)alkenyl or (halo)alkynyl; R2 is CH2-R7, NH-R7, O-R7, S-R7, SO-R7, SO2-R7, CH2O-R7 or O-X-R7, where X is alkylene, alkenylene or alkynylene and R7 is (un)substituted aryl or heterocyclyl; R3 is (un)substituted alkyl or cycloalkyl; R5 is B, B-CO, B-O2C, B-NR8CO, B-NR8CS, B-SO2 or B-NR8SO2, where B is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl and R8 is H or alkyl; R4, R6 are independently H, (un)substituted alkyl, alkoxy, cycloalkyl, aryl or

10595108

heterocyclyl; or NR4R6 may form a ring; Y is H or alkyl (with provisos)] or diastereomers or salts for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compds. II which can be reacted with an amide anion to produce compds. I. Thus, peptide III was prepared via peptide coupling in solution with cleavage of the azalactone intermediate by sulfamoylpyrroline in the last step.

IT 872497-04-6P 872497-05-7P 872497-09-1P
872497-10-4P 872497-12-6P 872497-13-7P
872497-16-0P 872497-17-1P 872497-18-2P
872497-19-3P 872497-21-7P 872497-22-8P
872497-33-1P 872497-34-2P 872497-35-3P
872497-36-4P 872497-37-5P 872497-38-6P
872497-39-7P 872497-40-0P 872497-41-1P
872497-42-2P 872497-43-3P 872497-44-4P
872497-45-5P 872497-46-6P 872497-47-7P
872497-48-8P 872497-49-9P 872497-50-2P
872497-51-3P 872497-52-4P 872497-53-5P
872497-54-6P 872497-55-7P 872497-56-8P
872497-57-9P 872497-58-0P 872497-59-1P
872497-60-4P 872497-61-5P 872497-62-6P
872497-63-7P 872497-64-8P 872497-65-9P
872497-66-0P 872497-67-1P 872497-68-2P
872497-69-3P 872497-70-6P 872497-71-7P
872497-72-8P 872497-73-9P 872497-74-0P
872497-75-1P 872497-76-2P 872497-77-3P
872497-78-4P 872497-79-5P 872497-80-8P
872497-81-9P 872497-82-0P 872497-83-1P
872497-84-2P 872497-85-3P 872497-86-4P
872497-87-5P 872497-88-6P 872497-89-7P
872497-90-0P 872497-91-1P 872497-92-2P
872497-93-3P 872497-94-4P 872497-95-5P
872497-96-6P 872497-97-7P 872497-98-8P
872497-99-9P 872498-00-5P 872498-01-6P
872498-02-7P 872498-03-8P 872498-04-9P
872498-05-0P 872498-06-1P 872498-07-2P
872498-08-3P 872498-09-4P 872498-10-7P
872498-11-8P 872498-12-9P 872498-13-0P
872498-14-1P 872498-15-2P 872498-16-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide analogs as hepatitis C inhibitors)

RN 872497-04-6 HCPLUS
CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10595108



RN 872497-05-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy) carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl) oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-04-6

CMF C36 H49 Cl N6 O9 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

Updated Search

10595108


CMF C2 H F3 O2



RN 872497-09-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-10-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 872497-09-1

CMF C40 H54 N6 O10 S


Absolute stereochemistry.

10595108



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 872497-12-6 HCAPLUS
CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-
[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10595108



RN 872497-13-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-12-6

CMF C37 H51 Br N6 O10 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

Updated Search

10595108

CMF C2 H F3 O2




RN 872497-16-0 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 872497-17-1 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-

Updated Search

10595108


(4-morpholinylsulfonyl)-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1


CRN 872497-16-0
CMF C38 H52 N6 O10 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2


10595108



RN 872497-18-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-19-3 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 872497-18-2

CMF C36 H50 N6 O9 S


Absolute stereochemistry.

10595108



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 872497-21-7 HCAPLUS
CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10595108



RN 872497-22-8 HCAPLUS


CN Cyclopropanecarboxamide, N-[cyclopentyloxy]carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-21-7

CMF C35 H48 N6 O8 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1

Updated Search

10595108


CMF C2 H F3 O2



RN 872497-33-1 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-34-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(bis(1-methylethyl)amino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10595108




RN 872497-35-3 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




Updated Search



RN 872497-36-4 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-37-5 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(3-(dimethylamino)-1-pyrrolidinyl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10595108




RN 872497-38-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10595108

PAGE 2-A




RN 872497-39-7 HCPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872497-40-0 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

10595108


Absolute stereochemistry.



RN 872497-41-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2-cyanoethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-42-2 HCAPLUS

Updated Search

10595108

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-proyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-43-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-44-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-proyl-1-amino-N-[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-45-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(2-pyridinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-46-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10595108

PAGE 1-A



PAGE 2-A





RN 872497-47-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyl)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 872497-48-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-49-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 872497-50-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-51-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(ethylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10595108




RN 872497-52-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)thio]-2-ethoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




Updated Search



RN 872497-53-5 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(2-methylpropyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-54-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)sulfonyl]-2-ethoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 872497-55-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(phenylmethyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-56-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

10595108


Absolute stereochemistry.



RN 872497-57-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy) carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl) oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-58-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy) carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl) oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-59-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-60-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-61-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-62-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-63-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-64-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-65-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-66-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-67-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-(methylthio)-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 872497-68-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-69-3 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-70-6 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-71-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[{(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-72-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[{(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-73-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-74-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-(methylthio)-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-75-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-(methylthio)-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-76-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-77-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-78-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-79-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-80-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-81-9 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-82-0 HCPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 872497-83-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy) carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl) oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-84-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy) carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl) oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872497-85-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-(methylthio)-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-86-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

10595108


Absolute stereochemistry.



RN 872497-87-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-88-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-[(ethoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

10595108


Absolute stereochemistry.



RN 872497-89-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylpropoxymethyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-90-0 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-

Updated Search

10595108

ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-91-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-92-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 872497-93-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-94-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10595108

PAGE 1-A




PAGE 2-A



RN 872497-95-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[[(cyanomethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-96-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylpropylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10595108




RN 872497-97-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(3-hydroxy-1-pyrrolidinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872497-98-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[[ethyl(2-hydroxyethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

10595108


Absolute stereochemistry.



RN 872497-99-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-00-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(3-carboxy-1-piperidinyl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872498-01-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-02-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(4-chlorophenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872498-03-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(4-carboxyphenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-04-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10595108

PAGE 1-A




PAGE 2-A



RN 872498-05-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(thieno[3,2-b]pyridin-7-yloxy)-L-prolyl-1-amino-N-((dimethylamino)sulfonyl)]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-06-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxythieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-((dimethylamino)sulfonyl)]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

10595108


Absolute stereochemistry.



RN 872498-07-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-phenyl-2-propynyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-08-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-cyano-6-ethoxythieno[2,3-b]pyridin-4-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 872498-09-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-10-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872498-11-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-12-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-[(1-methylethyl)sulfonyl]thieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 872498-13-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-methyl-5-(1-methylethoxy)thieno[3,2-b]pyridin-7-yl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-14-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-methyl-5-(2-propenyloxy)thieno[3,2-b]pyridin-7-yl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 872498-15-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-(methylsulfonyl)thieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-16-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-2,3-dimethylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1037097 HCAPLUS

DOCUMENT NUMBER: 142:38535

TITLE: Preparation of heterocyclic peptides as hepatitis C inhibitors

INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.; Bhardwaj, Punit; Bordeleau, Josee; Forgione, Pasquale; Ghiro, Elise; Gorys, Vida; Goudreau, Nathalie; Goulet, Sylvie; Halmos, Teddy; Rancourt, Jean

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103996	A1	20041202	WO 2004-CA750	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240704	A1	20041202	AU 2004-240704	20040519
CA 2522577	A1	20041202	CA 2004-2522577	20040519
EP 1654261	A1	20060510	EP 2004-733750	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

10595108

BR 2004010456
CN 1791599
JP 2006528937
US 2005020503
NO 2005006047
PRIORITY APPLN. INFO.:


A 20060606
A 20060621
T 20061228
A1 20050127
A 20060131

BR 2004-10456
CN 2004-80013783
JP 2006-529495
US 2004-850101
NO 2005-6047
US 2003-472709P
WO 2004-CA750

20040519
20040519
20040519
20040520
20051219
P 20030521
W 20040519

OTHER SOURCE(S):
GI

MARPAT 142:38535



AB Peptides I [B, R3 are (un)substituted alkyl, cycloalkyl or alkylcycloalkyl; X is O or NH; R1 is Et or vinyl; RC is OH or NHSO2RS, where RS is (cyclo)alkyl, alkylcycloalkyl, Ph, naphthyl, pyridinyl or an amino group, which are optionally substituted; R2 is R20, -NR22COR20, -NR22CO2R20, -NR22R21 or -NR22CONR21R23, where N20 is any group given for B; R21 is H or R20; R22, R23 are H or Me; L0 is H, OH, alkoxy, NH2, mono- or dialkylamino; L1, L2 are independently H, alkyl, alkoxy, alkylthio, -sulfinyl, or -sulfonyl; one of L1 and L2 may also be H; L0 and L1 or L1 and L2 may be covalently bonded to form a 5- or 6-membered ring] or their racemates, diastereoisomers, optical isomers or pharmaceutically-acceptable salts or esters were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease and are useful for the treatment of hepatitis C viral infection. Thus, I (B-X = cyclopentyloxy, R1 = vinyl, R2 = NHCOCH2CMe3, RC = OH, L1 = Me, L0 = MeO, L2 = H) was prepared via peptide coupling and Mitsunobu etherification reactions. The thiazole ring was formed by reaction of a 2-(bromoacetyl)quinoline derivative with N-neopentylthiourea. Compds. I show detectable plasma levels in the rat at 1 h and 2 h after an oral dose of 5 mg/kg.

IT 801286-05-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic peptides as hepatitis C inhibitors)


RN 801286-05-5 HCPLUS

CN Cyclopropanecarboxamide, 3-methyl-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-L-valyl-(4R)-4-[[7-methoxy-8-methyl-2-[2-[(1-

10595108

[methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[
[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:52:41 ON 12 APR 2007)

FILE 'REGISTRY' ENTERED AT 17:52:51 ON 12 APR 2007

L1 STRUCTURE uploaded
L2 20 S L1
L3 394 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:56:43 ON 12 APR 2007

L4 115 S L3

FILE 'REGISTRY' ENTERED AT 18:18:23 ON 12 APR 2007

L5 STRUCTURE uploaded
L6 7 S L5
L7 120 S L5 FULL

FILE 'HCAPLUS' ENTERED AT 18:19:26 ON 12 APR 2007

L8 3 S L7
L9 2 S L8 AND BAILEY, M?/AU

=> s 18 not 19
L10 1 L8 NOT L9

=> s 110 and bhardwaj, p?/au
34 BHARDWAJ, P?/AU
L11 0 L10 AND BHARDWAJ, P?/AU

Updated Search

10595108

=> s l10 and forgione, p?/au
82 FORGIONE, P?/AU
L12 0 L10 AND FORGIONE, P?/AU

=> d l10, ibib abs hitstr, 1

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:451218 HCAPLUS
DOCUMENT NUMBER: 142:482325
TITLE: Preparation of prolyl peptides as hepatitis C virus
inhibitors
INVENTOR(S): Scola, Paul Michael; McPhee, Fiona; Meanwell, Nicholas
A.; Hewawasam, Piyasena; Campbell, Jeffrey Allen
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046712	A1	20050526	WO 2004-US38165	20041112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005187165	A1	20050825	US 2004-985106	20041110
US 7132504	B2	20061107		
EP 1687018	A1	20060809	EP 2004-811049	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
NO 2006002267	A	20060804	NO 2006-2267	20060519
PRIORITY APPLN. INFO.:			US 2003-519124P	P 20031112
			WO 2004-US38165	W 20041112

OTHER SOURCE(S): MARPAT 142:482325
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention discloses peptides I [R1, R2 are independently alkyl, cycloalkyl, alkylcycloalkyl, alkoxy, aryl, alkylaryl, cycloalkylaryl, alkoxyaryl, cycloalkoxyaryl, heteroaryl or alkylheteroaryl; or NR1R2 is monocyclic heterocycl; m, n are 1 or 2; R3 is H, (halo)alk(en)yl or (halo)cycloalkyl; R4 is (un)substituted alkyl, alkenyl or cycloalkyl; Y is H, nitrophenyl, nitropyridyl or (un)substituted alkyl; B is H, alkyl, acyl, (thio)carbamoyl, sulfonyl or sulfamoyl; X is O, S, SO, SO2, OCH2,

10595108

CH₂O or NH; R' is (un)substituted heterocyclyl or aryl (with provisos) or their pharmaceutically-acceptable salts, solvates or prodrugs and methods for using them to inhibit the hepatitis C virus (HCV). Thus, compound II was prepared via peptide coupling in solution and showed IC₅₀ and EC₅₀ < 0.15 μM for inhibition of HCV NS3/4A protease.

IT 851795-10-3P 851795-11-4P 851795-12-5P
851795-13-6P 851795-14-7P 851795-15-8P
851795-16-9P 851795-17-0P 851795-18-1P
851795-19-2P 851795-20-5P 851795-21-6P
851795-22-7P 851795-23-8P 851795-24-9P
851795-25-0P 851795-26-1P 851795-27-2P
851795-28-3P 851795-29-4P 851795-30-7P
851795-31-8P 851795-33-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prolyl peptides as hepatitis C virus inhibitors)

RN 851795-10-3 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[{(ethylmethylamino)sulfonyl}-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-11-4 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[{(methoxymethylamino)sulfonyl}-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-12-5 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-13-6 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-14-7 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-15-8 HCPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-16-9 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[{methyl(1-methylethyl)amino}sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-17-0 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 851795-18-1 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-19-2 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-20-5 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(tetrahydro-2H-1,2-oxazin-2-yl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-21-6 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-22-7 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-23-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-24-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-25-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-26-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-27-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-28-3 HCPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-29-4 HCPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10595108



RN 851795-30-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851795-31-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1-isoquinolinyl)-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10595108



RN 851795-33-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(4-pyridinyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

23.61 456.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-2.34 -2.34

FILE 'CAOLD' ENTERED AT 18:21:28 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Updated Search

10595108

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 17:52:41 ON 12 APR 2007)

FILE 'REGISTRY' ENTERED AT 17:52:51 ON 12 APR 2007

L1 STRUCTURE uploaded
L2 20 S L1
L3 394 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:56:43 ON 12 APR 2007

L4 115 S L3

FILE 'REGISTRY' ENTERED AT 18:18:23 ON 12 APR 2007

L5 STRUCTURE uploaded
L6 7 S L5
L7 120 S L5 FULL

FILE 'HCAPLUS' ENTERED AT 18:19:26 ON 12 APR 2007

L8 3 S L7
L9 2 S L8 AND BAILEY, M?/AU
L10 1 S L8 NOT L9
L11 0 S L10 AND BHARDWAJ, P?/AU
L12 0 S L10 AND FORGIONE, P?/AU

FILE 'CAOLD' ENTERED AT 18:21:28 ON 12 APR 2007

=> s 17
L13 0 L7